Physician profile

Anthony Herrera

San Diego, CA

NPI 1720220049

$2,645.40

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$634.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $885.96 2020-2023
Bard Peripheral Vascular, INC. $707.24 2019-2020
Medtronic, INC. $336.18 2022-2023 Abre
Angiodynamics, INC. $321.92 2022-2023 Alphavac
Siemens Medical Solutions USA, INC. $188.79 2022-2023 Multitom Rax, Artis Icono Floor, Naeotom Alpha
Terumo Medical Corporation $88.43 2022
Varian Medical Systems, INC. $74.57 2021
Microvention, INC. $42.31 2023 Lvis Junior

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony Herrera

$2,645.40

in general payments reported 2019-2025

Years
2019-2023
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/1297315/anthony-herrera

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.